Genmab, a global biotechnology company specializing in antibody medicines, recently celebrated the grand opening of its expanded U.S. site at the Princeton Forrestal Innovation Center.
The event brought together patient advocates and advisors, government officials, community leaders, and academic partners to celebrate Genmab’s growing presence in New Jersey’s thriving life sciences ecosystem.
Genmab has grown from 150+ employees in 2020 to more than 1,000 today. In 2024 alone, the company supported more than 30 nonprofit organizations across the state through charitable donations and volunteer efforts, including initiatives to advance STEM education among youth.
New Jersey has been an incubator for the life-sciences sector. The state is home to eight of the top 10 global biopharmaceutical companies, eight of the top 10 R&D companies, and more than 5,600 life-sciences establishments, according to business advocacy group Choose New Jersey New Jersey. The state’s current 22 million square feet of lab space is set to increase by 27% by 2026.
Speakers highlighted Genmab’s growing impact on patients, the region, and the life sciences sector. Jan van de Winkel, Ph.D., president and chief executive officer, outlined the company’s long-term vision to impact patient lives. Tim Sullivan, CEO of NJEDA, emphasized Genmab’s role in driving economic growth in New Jersey. Debbie Hart, CEO of BioNJ, spoke to the company’s leadership in the state’s thriving biotech ecosystem. Portia Badham, a patient advisor, shared a perspective on how Genmab is bringing the patient voice into innovation.
“This new site reflects Genmab’s strong commitment to New Jersey — not just as a place to grow our business, but as a hub of innovation, top talent, and collaboration,” said Chris Cozic, executive vice president and chief people officer, Genmab.
The new facility is on a 125-acre innovation campus and has workspaces designed to foster cross-functional collaboration and attract top regional talent.
This expansion reflects Genmab’s transformation from a research-focused company to a fully integrated biotech — discovering, developing, and commercializing its own medicines globally.
